Endometrial cancer patients and tibolone

A matched case-control study

Kwang Beom Lee, Jong Min Lee, Jae Kwan Lee, Chi Heum Cho

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Objective: To evaluate whether tibolone had adverse effects on the prognosis of endometrial cancer patients. Methods: In this retrospective matched case-control study, out of 396 patients with endometrial cancer from January 1997 to December 2002, 68 patients who underwent complete surgical staging were identified as tibolone users (cases). For each case, one control as tibolone non-user was matched for stage and grade of disease, in this order of priority (ratio users: non-users, 1:1). Results: There were no significant differences in age (p = 0.11), stage (p = 1.00), grade (p = 0.96) and treatment modality (p = 0.55) between two arms. The mean duration of follow-up for tibolone users and tibolone non-users is 48.0 months and 54.4 months, respectively (p = 0.12). In tibolone users, a total of four patients recurred and two out of four patients died of disease. In tibolone non-users, there were three recurrences and all of three patients died of disease. There were no significant differences in disease free survival (p = 0.52) and overall survival (p = 0.61) between two arms. And there was no significant difference in disease free survival according to the duration of tibolone use (p = 0.14). Conclusion: There was no evidence that tibolone had adverse effects on the disease free survival and overall survival of endometrial cancer patients. So, tibolone could be used in these patients.

Original languageEnglish
Pages (from-to)264-269
Number of pages6
JournalMaturitas
Volume55
Issue number3
DOIs
Publication statusPublished - 2006 Oct 20

Fingerprint

tibolone
Endometrial Neoplasms
Case-Control Studies
Disease-Free Survival

Keywords

  • Endometrial cancer patients
  • Survival
  • Tibolone

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Obstetrics and Gynaecology

Cite this

Endometrial cancer patients and tibolone : A matched case-control study. / Lee, Kwang Beom; Lee, Jong Min; Lee, Jae Kwan; Cho, Chi Heum.

In: Maturitas, Vol. 55, No. 3, 20.10.2006, p. 264-269.

Research output: Contribution to journalArticle

Lee, Kwang Beom ; Lee, Jong Min ; Lee, Jae Kwan ; Cho, Chi Heum. / Endometrial cancer patients and tibolone : A matched case-control study. In: Maturitas. 2006 ; Vol. 55, No. 3. pp. 264-269.
@article{b17f85fb776b412ca3f5d245795dca18,
title = "Endometrial cancer patients and tibolone: A matched case-control study",
abstract = "Objective: To evaluate whether tibolone had adverse effects on the prognosis of endometrial cancer patients. Methods: In this retrospective matched case-control study, out of 396 patients with endometrial cancer from January 1997 to December 2002, 68 patients who underwent complete surgical staging were identified as tibolone users (cases). For each case, one control as tibolone non-user was matched for stage and grade of disease, in this order of priority (ratio users: non-users, 1:1). Results: There were no significant differences in age (p = 0.11), stage (p = 1.00), grade (p = 0.96) and treatment modality (p = 0.55) between two arms. The mean duration of follow-up for tibolone users and tibolone non-users is 48.0 months and 54.4 months, respectively (p = 0.12). In tibolone users, a total of four patients recurred and two out of four patients died of disease. In tibolone non-users, there were three recurrences and all of three patients died of disease. There were no significant differences in disease free survival (p = 0.52) and overall survival (p = 0.61) between two arms. And there was no significant difference in disease free survival according to the duration of tibolone use (p = 0.14). Conclusion: There was no evidence that tibolone had adverse effects on the disease free survival and overall survival of endometrial cancer patients. So, tibolone could be used in these patients.",
keywords = "Endometrial cancer patients, Survival, Tibolone",
author = "Lee, {Kwang Beom} and Lee, {Jong Min} and Lee, {Jae Kwan} and Cho, {Chi Heum}",
year = "2006",
month = "10",
day = "20",
doi = "10.1016/j.maturitas.2006.03.012",
language = "English",
volume = "55",
pages = "264--269",
journal = "Maturitas",
issn = "0378-5122",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Endometrial cancer patients and tibolone

T2 - A matched case-control study

AU - Lee, Kwang Beom

AU - Lee, Jong Min

AU - Lee, Jae Kwan

AU - Cho, Chi Heum

PY - 2006/10/20

Y1 - 2006/10/20

N2 - Objective: To evaluate whether tibolone had adverse effects on the prognosis of endometrial cancer patients. Methods: In this retrospective matched case-control study, out of 396 patients with endometrial cancer from January 1997 to December 2002, 68 patients who underwent complete surgical staging were identified as tibolone users (cases). For each case, one control as tibolone non-user was matched for stage and grade of disease, in this order of priority (ratio users: non-users, 1:1). Results: There were no significant differences in age (p = 0.11), stage (p = 1.00), grade (p = 0.96) and treatment modality (p = 0.55) between two arms. The mean duration of follow-up for tibolone users and tibolone non-users is 48.0 months and 54.4 months, respectively (p = 0.12). In tibolone users, a total of four patients recurred and two out of four patients died of disease. In tibolone non-users, there were three recurrences and all of three patients died of disease. There were no significant differences in disease free survival (p = 0.52) and overall survival (p = 0.61) between two arms. And there was no significant difference in disease free survival according to the duration of tibolone use (p = 0.14). Conclusion: There was no evidence that tibolone had adverse effects on the disease free survival and overall survival of endometrial cancer patients. So, tibolone could be used in these patients.

AB - Objective: To evaluate whether tibolone had adverse effects on the prognosis of endometrial cancer patients. Methods: In this retrospective matched case-control study, out of 396 patients with endometrial cancer from January 1997 to December 2002, 68 patients who underwent complete surgical staging were identified as tibolone users (cases). For each case, one control as tibolone non-user was matched for stage and grade of disease, in this order of priority (ratio users: non-users, 1:1). Results: There were no significant differences in age (p = 0.11), stage (p = 1.00), grade (p = 0.96) and treatment modality (p = 0.55) between two arms. The mean duration of follow-up for tibolone users and tibolone non-users is 48.0 months and 54.4 months, respectively (p = 0.12). In tibolone users, a total of four patients recurred and two out of four patients died of disease. In tibolone non-users, there were three recurrences and all of three patients died of disease. There were no significant differences in disease free survival (p = 0.52) and overall survival (p = 0.61) between two arms. And there was no significant difference in disease free survival according to the duration of tibolone use (p = 0.14). Conclusion: There was no evidence that tibolone had adverse effects on the disease free survival and overall survival of endometrial cancer patients. So, tibolone could be used in these patients.

KW - Endometrial cancer patients

KW - Survival

KW - Tibolone

UR - http://www.scopus.com/inward/record.url?scp=33748710040&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748710040&partnerID=8YFLogxK

U2 - 10.1016/j.maturitas.2006.03.012

DO - 10.1016/j.maturitas.2006.03.012

M3 - Article

VL - 55

SP - 264

EP - 269

JO - Maturitas

JF - Maturitas

SN - 0378-5122

IS - 3

ER -